Blackstone entered a new collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza program.   Under the agreement, Blackstone will provide up to $750 million to fund Moderna’s flu program and if successful, BXLS will be eligible to receive milestones and royalties on resultant flu products. Moderna will recognize the funding as a reduction in research...